Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Talaparib is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer: For the treatment of advanced breast cancer with Talazoparib, patients should be selected based on the presence of germline BRCA mutations. HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer: For the treatment of HRR gene-mutated mCRPC with Talazoparib, patients should be selected based on the presence of HRR gene mutations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C).Recommended Dosage for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer: The recommended dosage of Talazoparib is 1 mg taken orally once daily until disease progression or unacceptable toxicity. For adverse reactions, dosing interruption or dose reduction should be considered.Recommended Dosage for HRR Gene-mutated mCRPC: The recommended dosage of Talazoparib is 0.5 mg taken orally once daily in combination with Enzalutamide until disease progression or unacceptable toxicity. Talazoparib should be taken with or without food. Talazoparib capsules should be swallowed whole. It should not be opened or dissolved. If a patient vomits or misses a dose of Talazoparib, they should be instructed to take the next prescribed dose at the usual time.
Side Effects
Most common adverse reactions (>20%) as a single agent, including laboratory abnormalities, are: Hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased, fatigue, glucose increased, aspartate aminotransferase increased, alkaline phosphatase increased, alanine aminotransferase increased, calcium decreased, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.
Cautions & Contraindications
Warnings & Precautions
Myelodysplastic Syndrome/Acute Myeloid Leukemia: Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received Talaparib. If MDS/AML is confirmed, discontinue Talaparib.Myelosuppression: Myelosuppression consisting of anemia, neutropenia, and/or thrombocytopenia, have been reported in patients treated with Talaparib. If hematological toxicities do not resolve within 28 days, discontinue Talaparib and refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics.Embryo-Fetal Toxicity: Based on its mechanism of action and findings from animal data, Talaparib can cause fetal harm when administered to a pregnant woman.Infertility: Based on animal studies, Talaparib may impair fertility in males of reproductive potential.